[go: up one dir, main page]

WO1993025533A1 - Procedes et reactifs pour le dosage d'immnosuppresseurs - Google Patents

Procedes et reactifs pour le dosage d'immnosuppresseurs Download PDF

Info

Publication number
WO1993025533A1
WO1993025533A1 PCT/US1993/005197 US9305197W WO9325533A1 WO 1993025533 A1 WO1993025533 A1 WO 1993025533A1 US 9305197 W US9305197 W US 9305197W WO 9325533 A1 WO9325533 A1 WO 9325533A1
Authority
WO
WIPO (PCT)
Prior art keywords
immunosuppressant
binding
protein
reagent
detectable
Prior art date
Application number
PCT/US1993/005197
Other languages
English (en)
Inventor
Benjamin Clay Lane
Jay Richard Luly
Allan H. Smith
Timothy J. Bolling
Wldozimierz Mandecki
Tami J. Pilot-Matias
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to AU44005/93A priority Critical patent/AU4400593A/en
Publication of WO1993025533A1 publication Critical patent/WO1993025533A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Definitions

  • the present invention relates to the determination of immunosuppressive agents in a test sample.
  • the present invention relates to quantitative assays for immunosuppressive agents, and immunophilins of such immunosuppressive agents, employing recombinant fusion proteins comprising a specific binding protein for an immunosuppressive agent and a heterologous protein.
  • Immunosuppressive agents such as FK-506, cyclosporin and rapamycin are macrocyclic drugs of Streptomycete origin having in vivo and in vitro immunosuppressive properties [A. W. Thomson, Immunol. Today. Volume 10, pages 6-9 (1989), and B. D. Kahan, et. al., Transp. , Volume 52, pages 185-191 (1991)].
  • Such immunosuppressive agents appear to selectively act on T lymphocytes and inhibit the production of, or responses to, T lymphocyte growth and differentiation enhancing lymphokines such as interleukin-2 (T -2 ) [F. J. Dumont, et. al., J. Immunol..
  • European Patent Application Publication Number 184,162 describes the macrolide immunosuppressant FK-506 which is effective in the dose range of between 0.2 ng/mL and 2.0 ng/ml in plasma [W. J. Jusko, et al., Transp. Proc. Volume 23, No. 6, pages 2732-2735 (1991)] and 15 to 20 ng/mL in whole blood [Japanese FK-506 Study Group, Transp. Proc. Volume 23, No. 6, pages 3071-3074 (1991). Accordingly, the monitoring of therapeutic drug levels of such immunosuppressive agents in biological fluids has become very useful to provide physicians with information to aid in patient management The monitoring of such
  • SUBSTITUTE SHEET immunosuppressive agent levels enables adjustment of patient dosage to achieve optimal therapeutic effects, and helps avoid either subtherapeutic or toxic levels.
  • FK-506 in vivo evaluations of FK-506 have demonstrated toxic effects [J. J. Fung, et al., Transp. Proc. Volume 23, pages 3105-3108 (1991) and T. Ochiai, et al, Transp. Proc. Volume 23, pages 2718-2721 (1991)].
  • initial trials with FK-506 suggest that careful maintenance of whole blood levels can minimize the toxic effects while maximizing immunosuppressive efficacy [Japanese FK-506 Study Group, Transp. Proc. Volume 23, pages 3071-3074 and 3085-3088 (1991)].
  • Macrolide immunosuppressive agents have been quantitated in solution or bodily fluids at concentrations of 50 ng ml or higher using high performance liquid chromatography and detection by ultraviolet absorbance [M. C. Friob, et al., Transp. Proc. Volume 23, pages 2750-2752 (1991) and K. L. Napoli, et. al.,
  • Tissues which are the target for macrolide immunosuppressive agents such as FK506 and rapamycin contain protein receptors, known as immunophilins or immunosuppressant binding proteins, which specifically bind to their respective immunosuppressive agent [J. Siekierka, et. al., Nature. Volume 341, pages 755- 757 (1989) and M. Harding, et.
  • FKBP FK-506 binding protein
  • binding protein can be used to determine the presence or quantity of biologically useful ligand (European Patent Publication Number 379,342), or may be used to purify material binding to FKBP-ligand complexes such as a calcium/calmodulin phosphatase whose interaction with the FKBP-ligand complex may be especially relevant to the immunosuppressive actions of FK-506 [J. Liu, et al., Cell. Volume 66, pages 807-815 (March 1991)], whereby a glutathione S-transferase-FKBP fusion protein was used in place of FKBP.
  • FKBP FKBP
  • FKBP passive adsorption
  • the present invention provides assay methods and reagents for evaluating immunophilin ligands such as immunosuppressive agents and other agents capable of binding to immunosuppressant binding proteins, and immunophilins thereof, in a test sample from a patient undergoing therapeutic treatment therewith.
  • immunophilin ligands such as immunosuppressive agents and other agents capable of binding to immunosuppressant binding proteins, and immunophilins thereof, in a test sample from a patient undergoing therapeutic treatment therewith.
  • Such evaluation is accomplished employing an immunosuppressant assay reagent according to the present invention in a binding assay format whereby the amount or presence of such immunophilin ligands or i munophilins can be determined or, alternatively, the immunosuppressive activities of immunosuppressive agents and immunosuppressive metabolites can be evaluated in order to determine the efficacy of an administered immunosuppressive agent during the course of therapeutic treatment of a patient therewith.
  • the immunosuppressant assay reagent of the present invention is a recombinant fusion protein comprising (i) an immunosuppressant binding protein and (ii) a heterologous protein.
  • the immunosuppressant binding protein of the immunosuppressant assay reagent, as contemplated by the present invention, is a protein which is capable of binding to an immunophilin ligand.
  • the heterologous protein of the immunosuppressant assay reagent is a protein which is capable of being fused to the immunosuppressant binding protein, preferably CTP:CMP-3-deoxy-D- flt ⁇ /zo-octulosonate cytidylyl transferase, also known in the art as CMP-KDO synthetase or CKS, an enzyme derived from Escherichia coli (E. col ⁇ ), according to methods know in the art,
  • the immunosuppressant assay reagent of the present invention provides higher reactivity with the immunophilin ligand under determination than does the native immunosuppressant binding protein. Moreover, the present inventors have surprisingly and unexpectedly found that the heterologous protein component renders the immunosuppressant assay reagent more amenable than the native immunosuppressant binding protein to binding immunophilin ligands when immobilized to a solid support material.
  • an immunosuppressant assay reagent comprising FK-506 binding protein (FKBP) and CKS immobilized to a solid support material provides a higher signal-to-noise ratio when employed in a competitive heterogeneous assayformat than when native FKBP immobilized to a solid support material is employed in such assay format.
  • FKBP FK-506 binding protein
  • the present invention also provides compounds of the formulae:
  • R is selected from the group consisting of methyl, ethyl, propyl and allyl
  • Rl is OH or NH-X, wherein NH-X is a macromolecule or a detectable moiety, and
  • n is an integer from 0-6;
  • R2 is OH or NH-Y, wherein NH-Y is a macromolecule or a detectable moiety, all of which are useful for preparing reagents employed according to the methods of the present invention.
  • Figure 1 is a graphic representation of a DNA cloning vehicle for preparing the immunosuppressant assay reagent of the present invention.
  • Figure 2 compares the binding of an ascomycin-alkaline phosphatase detectable reagent of the present invention to immobilized forms of FKBP and the FKBP-CKS immunosuppressant assay reagent of the present invention as described in Example 9.
  • Figure 3 illustrates the inhibition of binding of an ascomycin-alkaline phosphatase detectable reagent to an immobilized form of the FKBP-CKS immunosuppressant assay reagent of the present invention by FK-506 and rapamycin as described in Example 9.
  • Figure 4 illustrates the total and nonspecific binding of a [ ⁇ H]-dihydro-FK- 506 detectable reagent to an immobilized form of the FKBP-CKS immunosuppressant assay reagent of the present invention as described in Example 10.
  • Figure 5 illustrates the total and nonspecific binding signal when a multicomponent ligand system is used as a detectable reagent for binding to an immobilized form of the FKBP-CKS immunosuppressant assay reagent of the present invention as described in Example 11.
  • Figure 6 illustrates the inhibition of a multicomponent ligand system from binding to an immobilized form of the FKBP-CKS immunosuppressant assay reagent of the present invention by FK-506, rapamycin, and ascomycin as described in Example 11.
  • Figures 7A and 7B illustrate the detection of ascomycin from mouse whole blood and plasma employing an immobilized form of the FKBP-CKS immunosuppressant assay reagent of the present invention as described in Example 12.
  • Figure 8 illustrates the binding of calcineurin to an immobilized form of the
  • Figure 9 illustrates the dependence of calcineurin binding to an immobilized form of the FKBP-CKS immunosuppressant assay reagent of the present invention on the concentration of FK-506 and ascomycin as described in Example 13.
  • Figure 10 illustrates the use of an immobilized form of the FKBP-CKS immunosuppressant assay reagent in an assay for FKBP binding activity as described in Example 14.
  • Figure 11 illustrates the use of an immobilized form of the FKBP-CKS immunosuppressant assay reagent of the present invention in an assay for FK-506 wherein the immunosuppressant assay reagent is immobilized to a solid phase material with polyclonal or monoclonal anti-CKS antibodies as described in Example 15a.
  • Figure 12 illustrates the ability of polyclonal and monoclonal anti-CKS antibodies to separate free ascomycin-alkaline phosphatase detectable reagent from detectable reagent bound to the FKBP-CKS immunosuppressant assay reagent of the present invention as described in Example 15b.
  • Figure 13 illustrates the synthetic pathway for preparing reagents of the present invention derived from ascomycin and ascomycin-analogs.
  • Figure 14 illustrates the synthetic pathway for preparing reagents of the present invention derived from rapamycin and rapamycin-analogs.
  • Immunophilin ligands which can be determined and evaluated according to the present invention include, but are not intended to be limited to, macrolide immunosuppressive agents, other agents capable of binding to immunosuppressant binding proteins, and the like.
  • immunophilin ligands contemplated by the present invention include, but are not intended to be limited to, FK-506, rapamycin, cyclosporin, ascomycin, and analogs and synthetic derivatives thereof, and the like.
  • Other immunophilin ligands contemplated by the present invention include, but are not intended to be limited to, non-macrocyclic compounds and non-immunosuppressive agents which are capable of interacting with immunosuppressant binding proteins, such as those described in International Patent Application Publication No. WO/92-04370, heat-shock proteins and glucocorticoid receptors [(P.-K.K. Tai, et al., Science. Volume 256, pages 1315-
  • immunophilin ligands also include their respective biologically-active metabolites, derivatives, and analogs thereof.
  • Immunophilin ligand-analogs include those substances which cross-react with an immunosuppressant binding protein for the immunophilin ligand of interest, although it may do so to a greater or lesser extent than does the immunophilin ligand itself.
  • the immunophilin ligand-analog can include a modified immunophilin ligand-analog as well as a fragmented or synthetic portion of the immunophilin ligand molecule, provided that the immunophilin ligand-analog has at least one epitopic site in common with the immunophilin ligand of interest.
  • an immunophilin ligand-analog can be a synthetic peptide sequence which duplicates or mimics at least one epitope of the whole immunophilin ligand molecule so that the immunophilin ligand-analog can bind to an immunophilin.
  • Other immunophilin ligands which can be determined and evaluated according to the present invention include those immunophilin ligands obtained from fermentation, chemical synthesis, and the like.
  • the immunosuppressant assay reagent of the present invention is a recombinant fusion protein comprising an immunosuppressant binding protein and a heterologous protein, wherein the immunosuppressant binding protein can be fused to a heterologous protein according to methods known in the art.
  • Immunosuppressant binding proteins contemplated by the present invention are specific binding proteins capable of binding to the immunosuppressive agent under determination and include, but are not intended to be limited to FK-506-binding protein, rapamycin-binding protein, cyclosporin-binding protein, and the like.
  • FKBP- 12 the predominant FKBP found in T-cells has been identified as FKBP- 12
  • other immunosuppressant binding proteins which have been derived from multigene families, such as FKBP- 13, FKBP-25, and cyclophilin, are contemplated by the present invention.
  • the characteristics of the immunosuppressant binding proteins are such that they may crossreact with some immunophilin ligands, wherein the specificity of the various assay methods and immunosuppressant assay reagent of the present invention will be mirrored by the specificity of the interaction between the immunosuppressant binding protein and the immunophilin ligand.
  • FKBP- 13 the predominant FKBP found in T-cells
  • cyclophilin the characteristics of the immunosuppressant binding proteins are such that they may crossreact with some immunophilin ligands, wherein the specificity of the various assay methods and immunosuppressant assay reagent of the present invention will be mirrored by the specificity of the interaction between the immunosup
  • CKS immunosuppressant assay reagent of the present invention as described herein, either FK-506, ascomycin, or rapamycin, would be detected, whereas cyclosporin A would not
  • cyclosporin binding protein (cycloph ⁇ lin)-CKS immunosuppressant assay reagent of the present invention cyclosporins would be detected whereas FK-506, ascomycin or rapamycin would not.
  • the heterologous protein is a protein, other than the immunosuppressant binding protein, which preferably has little or no specific binding reactivity with the immunophilin ligand of interest
  • the heterologous protein preferably provides sufficient bulk or mass to allow immobilization of the immunosuppressant assay reagent to a solid phase material as described herein while, at the same time, retaining binding activity of the immunosuppressant assay reagent for immunophilin ligands.
  • Such heterologous proteins include, but are not intended to be limited to, CKS; glutathione S-transferase; the Fc portion of immunoglobulin molecules; and the like.
  • prokaryotic or eukaryotic proteins can be expressed in hosts where such proteins are not normally present, i.e., proteins which are heterologous to the host.
  • protein expression is accomplished in a recombinant fusion system by inserting the deoxyribonucleic acid (DNA) sequence which codes for the protein of interest downstream from a control region (e.g., a lac operon) in plasmid DNA, which plasmid is inserted into the cell to transform the cell so it can produce (or express) the fusion protein of interest ( Figure 1).
  • DNA deoxyribonucleic acid
  • the carrier portion of a hybrid gene typically found on the 5' end of the gene, provides the regulatory regions for transcription and translation as well as providing the genetic code for a peptide which facilitates detection [Shuman, et al., J. Biol. Chem.. Volume 255, page 168 (1980)] and purification [(Moks, et al., Bio/Technology. Volume 5, page 379
  • the immunosuppressant assay reagent is a recombinant fusion protein comprising an immunosuppressant binding protein and CKS.
  • fusion protein can be prepared according to the methods described in copending U.S. Patent Application Serial No. 276,263, filed November 23, entitled "CKS Method Of Protein Synthesis and in Biotechniques. Volume 8, pages 488-490 (1990), both of which are incorporated herein by reference. According to such method, a fusion protein of CKS and a heterologous protein is expressed in cells transformed with a cloning vehicle which has a DNA insert coding for CKS and the heterologous protein.
  • Such DNA cloning vehicle includes a control region, a region coding at least a portion of CKS, and a region coding for the protein of interest.
  • the control region includes a modified lac promoter which is essentially native lacP from -73 to +21 with a deletion at -24 of one Guanine/Cytosine nucleic acid base pair and a deletion at the -9 position, and directs expression of the coding regions.
  • the control region also includes a synthetic ribosome binding site (nt 31-39) which is homologous to the 3' end of the 16S ribosomal ribonucleic acid (rRNA) in E. Coli.
  • the method for expressing a protein in such fusion system comprises the steps of (i) providing a DNA cloning vehicle as described above, (ii) transforming a microbe with such DNA cloning vehicle, and (iii) expressing the fusion protein comprising the protein of interest and CKS.
  • the immunosuppressant assay reagent comprises a recombinant FKBP-CKS fusion protein.
  • fusion protein can be prepared by isolating the human FKBP gene from a Jurkat T cell cDNA library and incorporating it into an E. coli expression vector containing the CKS gene under the control of a lac promoter.
  • the DNA for FKBP-CKS fusion protein was prepared from the FKBP gene by cloning into an expression vector containing the CKS gene under the control of a modified lac promoter as described by T. Boiling and W. Mandecki, Biotechniques. Volume 8, pages 488-490 (1990).
  • the fusion protein preparation was obtained from lysed E. coli by 25 to 35% ammonium sulfate fractionation. Cytosols from cells expressing the FKBP-CKS fusion protein or purified FKBP-CKS fusion protein can be employed in various assay formats according to the present invention.
  • the immunosuppressant assay reagent of the present invention can be employed in various assay formats for determining the presence or amount of immunophilin ligands or immunophilins in a test sample.
  • the immunophilin ligand is an immunosuppressive agent
  • the immunosuppressive assay reagent can be employed in an assay format for evaluating the immunosuppressive efficacy of such immunosuppressive agents in a test sample.
  • the test sample can be any material containing an immunophilin ligand, and can be used directly as obtained from the source or following a pretreatment to modify the character of the sample.
  • the test sample can be derived from any chemical or biological source, such as a physiological fluid, including but not limited to, whole blood, serum, plasma, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, amniotic fluid, and the like, and fermentation broths, cell cultures, and chemical reaction mixtures.
  • a physiological fluid including but not limited to, whole blood, serum, plasma, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, amniotic fluid, and the like, and fermentation broths, cell cultures, and chemical reaction mixtures.
  • the test sample can be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like, to separate other components from the test sample which may cause interference in the binding assay.
  • methods of pretreatment can involve filtration, distillation, centrifugation, concentration, inactivation of interfering components, and addition of reagents such as detergents for cell lysis and solubilization of an immunosuppressant binding protein, extraction with organic solvents, and the like.
  • reagents such as detergents for cell lysis and solubilization of an immunosuppressant binding protein, extraction with organic solvents, and the like.
  • the determination of immunophilin ligands or immunophilins and evaluation of immunosuppressive agents employing the immunosuppressant assay reagent of the present invention can be performed according to various specific binding assay formats known in the art including, but not intended to be limited to, homogeneous specific binding assay formats, heterogeneous assay formats, inhibition assay formats, heterogeneous immunoassay formats, homogeneous immunoassay formats, and the like, where the amount of a detectable reagent employed therein can be measured and correlated to the amount of an immunophilin ligand or immunophilin, or immunosuppressive activity of an immunosuppressive agent, in a test sample.
  • the various reagent addition steps can be performed simultaneously or sequentially.
  • the detectable reagent can be either the immunophilin ligand or analog thereof labeled with a detectable moiety, or an immunophilin or immunoreactant labeled with a detectable moiety.
  • the detectable moiety can be any compound or conventional detectable chemical group having a detectable physical or chemical property which can be used to label an immunophilin ligand, an immunophilin, or an immunoreactant.
  • an immunoreactant such as in a homogeneous or heterogeneous assay format
  • such immunoreactant can be a polyclonal or monoclonal antibody, a recombinant protein or recombinant antibody, a chimeric antibody, mixtures or fragments thereof, as well as a preparation of such antibodies, peptides and nucleotides for which suitability for -use as specific binding members is well known to those skilled in the art.
  • detectable chemical groups include, but are not intended to be limited to, enzymatically active groups such as enzymes, enzyme substrates, prosthetic groups or coenzymes; spin labels; fluorescent molecules such as fluorescers and fluorogens; chromophores and chromogens; luminescent molecules such as chemiluminescers and bioluminescers; phosphorescent molecules; specifically bindable ligands such as biotin and avidin; electroactive species; radioisotopes; toxins; drugs; haptens; DNA; RNA; polysaccharides; polypeptides; liposomes; colored particles and colored microparticles; and the like.
  • homogeneous and heterogeneous assay formats depend upon the ability of (i) an immunophilin ligand or immunophilin in the presence of a detectable reagent comprising the immunophilin ligand or analog thereof, or an immunophilin, or an immunoreactant, labeled with a detectable chemical group, or (ii) in the case of an immunophilin, the ability of a detectable reagent comprising the immunophilin ligand or analog thereof labeled with a detectable chemical group, to specifically bind to the immunosuppressant binding protein component of the immunosuppressant assay reagent.
  • the extent of such binding is determined by the amount of the detectable chemical group present in the detectable reagent which either has or has not participated in a binding reaction with the immunophilin ligand, wherein the amount of the detectable reagent detected and measured can be correlated to the amount of the immunophilin ligand or immunophilin present in the test sample.
  • Homogeneous assays according to the present invention can be performed involving a competition between an immunophilin ligand from a test sample and a detectable reagent, comprising the immunophilin ligand or analog thereof labeled with a detectable chemical group, for a limited number of immunosuppressant binding protein sites of the immunosuppressant assay reagent.
  • immunophilin ligands can be determined according to the present invention in a fluorescent polarization assay employing a fluorescent detectable reagent, comprising the immunophilin ligand or analog thereof labeled with a fluorescent molecule, wherein the fluorescent detectable reagent, when excited by linearly polarized light, will emit fluorescence having a degree of polarization inversely related to its rate of rotation.
  • the fluorescent detectable reagent When the fluorescent detectable reagent is bound to the immunosuppressant assay reagent and excited by linearly polarized polarized light, it is constrained from rotating between the time light is absorbed and emitted whereas, when the unbound fluorescent detectable reagent is excited by linearly polarized light, its rotation is much faster than the corresponding bound fluorescent detectable reagent and the molecules are more randomly orientated so that the emitted light is polarized. Accordingly, when plane polarized light is passed through a solution containing the aforementioned reagents, a fluorescent polarization response is detected and correlated to the amount of the immunophilin ligand present in the test sample.
  • heterogeneous immunoassays can be performed involving binding reactions among an immunophilin ligand from a test sample, the immunosuppressant assay reagent of the present invention, and a detectable reagent comprising an immunophilin or immunoreactant for the immunophilin ligand labeled with a detectable chemical group, wherein the extent of binding of the detectable reagent to the immunophilin ligand is a function of the amount of the immunophilin ligand present in the test sample.
  • any of the detectable reagent not bound to the immunophilin ligand must be separated therefrom.
  • separation can be accomplished employing solid phase materials for the direct immobilization of the immunosuppressant assay reagent thereto according to methods known in the art such as adsorption techniques, covalent binding techniques, and the like.
  • the solid phase materials can be any solid material to which the immunosuppressant assay reagent can be immobilized and include, but are not intended to be limited to, beads, magnetic particles, micro or macro particles, test tubes, and microtiter plates.
  • Such solid phase materials can be made from synthetic materials, naturally occurring materials, or naturally occurring materials which have been synthetically modified, and include, but are not intended to be limited to, cellulose materials, such as paper, cellulose and cellulose derivatives such as cellulose acetate and nitrocellulose; fiberglass; naturally occurring cloth such as cotton; synthetic cloth such as nylon; porous gels, such as silica, agarose, dextran, and gelatin; porous fibrous matrixes; starch based materials, such as cross-linked dextran chains; ceramic materials; olefin or thermoplastic materials including polyvinyl chloride, polyethylene, polyvinyl acetate, polyamide, polycarbonate, polystyrene, copolymers of vinyl acetate and vinyl chloride, combinations of polyvinyl chloride-silica; and the like.
  • cellulose materials such as paper, cellulose and cellulose derivatives such as cellulose acetate and nitrocellulose
  • fiberglass naturally occurring cloth such as cotton
  • synthetic cloth such as nylon
  • porous gels such as si
  • a heterogeneous assay format which can be performed according to the present invention is a competitive format wherein the immunosuppressant assay reagent is immobilized to a solid phase material whereby upon separation, the amount of detectable reagent, comprising the immunophilin ligand or analog thereof labeled with a detectable chemical group, which is bound to such solid phase material can be detected and correlated to the amount of the immunophilin ligand present in the test sample.
  • heterogeneous assay format which can be performed according to the present invention is a sandwich assay format which involves contacting a test sample containing an immunophilin ligand with an immobilized form of the immunosuppressant assay reagent as described above, wherein the immunophilin ligand binds to the immobilized immunosuppressant assay reagent to form a complex therewith.
  • Such complex is then contacted with a detectable reagent comprising an immunophilin or immunoreactant for the immunophilin ligand, labeled with a detectable chemical group, and, following, for example, one or more washing steps to remove any unbound material, the detectable reagent bound to the complex is measured and correlated to the amount of the immunophilin ligand present in the test sample.
  • FK-506 and analogs thereof can be prepared employing FK-506 and analogs thereof, such as FK-523 and FK-525.
  • FK-506 and analogs thereof can be isolated, for example, from culture media obtained according to methods known in the art by fermentation of microorganisms of the genus Streptomyces, such as described in European Patent Application No. 0184162, available from the Fermentation Research Institute, Tsukuba, Ibaraki 305, Japan under the provisions of the Budapest Treaty, under deposit No. PERM BP-927 (redeposited on April 27, 1989 with the Agricultural Research Culture
  • FR-900520 European Patent Application 0184162
  • FR-900520 also known as ascomycin
  • FR-900520 Novel immunosuppressants isolated from A streptomyces. I. Taxonomy of the producing strain , J. Antibiot. 1988, XLI(11), 1586-1591; H. Hatanaka, T. Kino, S. Miyata, N. Inamura, A. Kuroda, T.
  • rapamycin can be produced by Streptomyces hygrosopicus, using conditions adapted from the literature [C. Vezina, A. Kudelski, S. N. Sehgal, J.
  • a preferred detectable reagent comprises an immunosuppressive agent labeled with a hydrolytic enzyme such as alkaline phosphatase or horseradish peroxidase.
  • a hydrolytic enzyme such as alkaline phosphatase or horseradish peroxidase.
  • ascomycin an analog of FK-506, and which can be used in a specific binding assay for FK-506, can be converted to its C22 O-carboxymethyloxime using O-carboxymethyl hydroxylamine ( Figure 13).
  • an activated ester can be prepared by reaction with N-hydroxysuccinimide and dicyclohexyl carbodiimide.
  • the ascomycin-alkaline phosphatase detectable reagent can catalyze the hydrolysis of various substrates to produce detectable signals, such as catalysis of p-nitrophenyl phosphate to produce a colorimetric signal; catalysis of 4-methyl umbelliferyl phosphate to produce a fluorimetric signal; catalysis of water-soluble 1,2-dioxetane derivatives (Tropix, Inc., Bedford, MA) to produce a chemiluminescent signal, and the like.
  • a radioactive detectable reagent [** * ⁇ ]-dihydro-FK-506, can be prepared by catalytic reduction of FK-506 using palladium on carbon and exposure to tritium gas, and subsequent purification of the radiolabelled compound can be achieved by thin layer chromatography or HPLC.
  • the present inventors when performing a heterogeneous assay employing a solid phase material as described above, the present inventors have surprisingly and unexpectedly found that the fusion of the heterologous protein to the immunosuppressant binding protein results in the retention of superior binding activity of the immunosuppressant binding protein when immobilized to a solid phase material.
  • the native form of the immunosuppressant binding protein lacks such superior binding activity when immobilized to a solid phase material.
  • an immunosuppressant assay reagent can be bound to a solid phase phase material through the use of an immunoreactant as described above, such as an antibody ( Figure 11) which is immobilized to the solid phase material according to methods known in the art and which binds to a region of the heterologous protein distant from the active site or desired antigenic site of the immunosuppressant binding protein.
  • an immunoreactant as described above, such as an antibody ( Figure 11) which is immobilized to the solid phase material according to methods known in the art and which binds to a region of the heterologous protein distant from the active site or desired antigenic site of the immunosuppressant binding protein.
  • Such "passive antibody” coupling technique also serves to conserve reagents. It is to be understood that the immunosuppressant assay reagent can be immobilized to the solid phase material prior to performance of the binding assay or formed in situ during the course of performing the binding assay.
  • the immunosuppressant assay reagent can be immobilized to a solid phase material by derivatizing the immunosuppressant assay reagent with a first binding member of a specific binding member pair, and coupling or linking a second binding member of the specific binding member pair to the solid phase material, wherein immobilization of the immunosuppressant assay reagent is achieved by binding of the first and second binding members.
  • binding pairs as contemplated herein are two different molecules wherein one of the molecules specifically binds to the second molecule through chemical or physical means.
  • binding pairs include, but are not intended to be limited to, analytes and antibodies, biotin and avidin, carbohydrates and lectins, complementary nucleotide sequences, complementary peptide sequences, effector and receptor molecules, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, a peptide sequence and an antibody specific for the sequence or the entire protein, polymeric acids and bases, dyes and protein binders, peptides and specific protein binders (e.g., ribonuclease, S- peptide and ribonuclease S-protein), and the like.
  • binding pairs can include members that are analogs of the original binding member, for example, an analyte-analog or a binding member made by recombinant techniques or molecular engineering, or an immunoreactant as defined above.
  • Another method by which the immunosuppressant assay reagent can be immobilized to a solid phase material is through chemical activation of the solid phase material in order to couple the immunosuppressant assay reagent thereto.
  • SepharoseTM resin particles can be activated with cyanogen bromide or diols by sodium periodate, or with free amines by formaldehyde, glutaraldehyde, and the like, wherein the immunosuppressant assay reagent irreversibly binds to such reactive groups.
  • the detectable reagent can be one which is capable of binding to the immunosuppressant assay reagent-immunophilin ligand complex while, at the same time, is capable of providing a detectable signal.
  • the detectable reagent is a calcium/calmodulin activated phosphatase, such as calcineurin, which is regulated by the calcium ion and calmodulin.
  • immunosuppressive agents such as FK-506 and analogs thereof are detected by their ability to enhance the binding of calcineurin to the immunosuppressant binding protein of the immunosuppressant assay reagent.
  • a binding assay for FK-506 and analogs thereof can be performed employing calcineurin and the immunosuppressant assay reagent of the present invention as described in Example 13.
  • the immunosuppressant assay reagent is immobilized to a solid phase material, such as the well walls of a microtiter plate, and a test sample containing an immunophilin ligand, particularly an immunosuppressive agent such as FK-506, and calcineurin are added thereto.
  • a substrate for calcineurin such as para-nitrophenyl phosphate
  • calcineurin such as para-nitrophenyl phosphate
  • a substrate for calcineurin such as para-nitrophenyl phosphate
  • para-nitrophenol a yellow product
  • the temporal change in 405 nm absorbance is measured and correlated to the amount of the immunosuppressive agent in the test sample.
  • some macrolide immunosuppressants such as FK-506 enhance the binding of calcineurin to the FKBP-CKS immunosuppressant assay agent and; therefore, increase the amount of para-nitrophenol product produced therefrom.
  • other macrolide immunosuppressants like rapamycin, are unable to enhance calcineurin binding to the FKBP-CKS and can not be directly measured with this method.
  • Figure 9 illustrates the ability of FK-506 and ascomycin to increase, in a concentration dependent manner, the amount of signal produced when such macrolide immunosuppressive agents are included in the assay format of Example 13. FK-506 and ascomycin are detected when they are present in the assay at concentrations greater than 1 nM. Since the level of signal is related to the concentration of the macrolide immunosuppressive agent, standard curves can be created to relate the known concentration of a purified FK-506 to the amount of signal produced and used to estimate the unknown amount of the FK-506 in a sample.
  • An assay for rapamycin and structurally similar molecules can also be performed based upon their ability to compete for FK-506 binding to the FKBP- CKS immunosuppressant assay reagent.
  • the assay is performed as described in Example 13 with the inclusion of a standard concentration of FK-506, preferably 10 nM, in the macrolide solution that contains rapamycin or a rapamycin-like molecule.
  • the amount of calcineurin bound to the immobilized FKBP-CKS immunosuppressant assay reagent in the wells is reduced in relation to the concentration of rapamycin.
  • a standard curve can be created to relate the known concentration of a purified rapamycin-like competitor to the amount of signal produced by the detectable reagent and used to estimate the unknown amount of the rapamycin-like competitor in a sample.
  • Other molecules known as competitors, can also bind to the immunosuppressant assay reagent wherein when binding thereto, they can prevent binding of the immunophilin ligand of interest and thereby reduce the amount of signal produced by the detectable reagent when standard amounts of the immunophilin ligand and the immunosuppressant assay reagent are coincubated with a test sample containing the competitor molecule. Quantitation of an unknown amount of competitor molecule in a test sample can be achieved by comparing the effect of the test sample and the effect of known amounts of the competitor molecule on the level of signal produced by the detectable reagent when they are coincubated with standard amounts of the immunosuppressant binding reagent and the immunophilin ligand.
  • immunosuppressive agents such as rapamycin and analogs thereof can be detected by their ability to inhibit the binding of calcineurin to the immunosuppressant binding protein of the immunosuppressant assay reagent When FK-506 and analogs thereof are also present. Quantitation of the amount of immunosuppressive agent in the test sample can be accomplished by comparison to a standard curve that relates the amount of calcineurin bound when known amounts of the immunosuppressive agent of interest is added to the assay format.
  • the immunosuppressant assay reagent of the present invention can also be used to determine the presence or amount of a immunosuppressant binding protein in order to aid in the prediction of efficacious therapeutic doses of an immunosuppressive agent and individual related toxicity. Such determination can be made in an inhibition assay format comprising a test sample containing the immunosuppressant binding protein of interest, an immobilized form of the immunosuppressant assay reagent of the present invention, and a detectable reagent comprising the immunophilin ligand or analog thereof labeled with a detectable moiety, wherein the immunophilin ligand is capable of binding to the immunosuppressant binding protein from the test sample.
  • binding of the immunosuppressant binding protein from the test sample to the detectable reagent will inhibit binding of the detectable reagent to the immobilized immunosuppressant assay reagent, wherein the amount of labeled reagent bound to the immobilized immunosuppressant assay reagent can be measured and correlated to the amount of the immunosuppressant binding protein present in the test sample.
  • Figure 10 illustrates the results of such inhibition assay format for the determination of FKBP wherein a FKBP-CKS immunosuppressant assay reagent immobilized to microtiter plate well walls was reacted with a detectable reagent comprising ascomycin labeled with alkaline phosphatase in the presence of increasing amounts of FKBP in the microtiter wells. Any of the detectable reagent which was not bound to the immobilized immunosuppressant assay reagent was washed from the wells, para-nitrophenyl phosphate was added to the wells, and the absorbance of the reaction between the substrate and the alkaline phosphatase was measured at 405 nm. It is to be understood that when making such determination, it may be necessary to treat the test sample, particularly where the test sample is, for example, whole blood, with a detergent in order to solubilize the immunosuppressant binding protein contained therein.
  • the immunosuppressant assay reagent can be used for isolation and purification of immunophilin ligands by immobilizing the immunosuppressant assay reagent of the present invention to a solid support material, such as in a column format, and contacting the immunosuppressant assay reagent with a test sample.
  • the immunophilin ligand can be recovered from the immunobilized immunosuppressant assay reagent by conditions which disrupt the binding interaction between the immunosuppressant assay reagent and the immunophilin ligand. For example, such binding interaction can be disrupted by raising or lowering the pH or by the use of protein denaturants such as urea, guanidinium, hydrochloric acid, sodium dodecyl sulfate, and the like.
  • test kit comprises all of the essential reagents required to perform a desired specific binding assay for an immunophilin ligand or immunophilin, or for the evaluation of the immunosuppressive activity of an immunosuppressive agent, as described herein.
  • the test kit is presented in a commercially packaged form as a combination of one or more containers holding the necessary reagents, as a composition or admixture where the compatibility of the reagents will allow.
  • Particularly preferred is a test kit for the determination of macrolide immunosuppressive agents in a heterogeneous binding assay format and wherein the immunosuppressant assay reagent comprises an immunosuppressant binding protein and CKS immobilized to a solid support material as described herein.
  • the test kit can, of course, include other materials as are known in the art and which may be desirable from a commercial user standpoint, such as buffers, diluents, pretreatment reagents, and the like.
  • the cells were lysed with 3-4 ml/gram of cells with a lysis buffer consisting of 50 mM phosphate, 10 mM EDTA, 10 mM magnesium chloride, pH 7.4, containing freshly added lysozyme (Sigma Chemical Co., St. Louis, MO) at 0.5 mg/ml with 5 mM DTT (U.S. Biochemicals, Cleveland, OH), 1 ug/ml of DNAase (Boehringer Mannheim, Indianapolis, IN), and 1 mM PMSF (Sigma Chemical Co.).
  • a lysis buffer consisting of 50 mM phosphate, 10 mM EDTA, 10 mM magnesium chloride, pH 7.4, containing freshly added lysozyme (Sigma Chemical Co., St. Louis, MO) at 0.5 mg/ml with 5 mM DTT (U.S. Biochemicals, Cleveland, OH), 1 ug/ml of DNAase (Boehringer Mannheim, Indianapolis, IN),
  • the cells were stirred at room temperature for 40-60 minutes followed by sonication on an ice bath with 1 minute pulses for 5-10 minutes, and the cells were checked for lysis on a microscope and centrifuged for 40 minutes at 9000 rpm in a GS3 Sorvall rotor.
  • the resultant lysant was subjected to 40-60% fractionation at 4°C and the precipitate was pelleted by centrifugation. The pellet was placed in dialysis tubing
  • the resulting precipitate was pelleted by centrifugation and dialyzed as described above, and stored in the presence of 0.004% sodium nitrate.
  • the purified protein was expressed as a non-fusion construct estimated at 5-10 mg per liter of harvested culture media.
  • An immunusuppressant assay reagent of the present invention comprising FKBP and CKS was prepared by isolating human FKBP from a Jurkat T cell cDNA library and incorporating it into an E. coli expression vector containing the CKS gene under the control of a lac promoter.
  • the DNA for FKBP-CKS fusion protein was prepared from the FKBP gene by cloning into an expression vector containing the CKS gene under the control of a modified lac promoter as described by copending U.S. Patent Application Serial No. 276,263, filed November 23, entitled "CKS Method Of Protein Synthesis and by T. Boiling and W. Mandecki, Biotechniques, Volume 8, pages 488-490 (1990).
  • the fusion protein preparation was obtained from lysed E. coli by 25 to 35% ammonium sulfate fractionation.
  • the reaction mixture was partitioned between ethyl acetate and 0.1 M H3PO4, and the ethyl acetate layer was washed with brine, dried over Na2S04, filtered, and concentrated to give 1.5 g of crude product.
  • the crude product was redissolved in dichloromethane (20 mL), filtered through a silica gel plug (20 mL), and eluted with 30% acetone/hexane (2 x 50 mL) to remove unreacted starting material, then 50% acetone/hexane (4 x 50 mL) to give 650 mg of the desired product in 60% yield.
  • Rapamycin-C32-Carboxymethyloxime (position 32, Figure 14, Compound V) is prepared by stirring a solution of rapamycin (1.26 mmol, 1.15 g), carboxymethoxylamine hemihydrochloride (1.52 mmol, 0.33 g) and N- methylmorpholine (2.78 mmol, 0.31 mL) in ethanol (5 mL), and allowed to react until the reaction was judged complete by TLC. The reaction mixture was evaporated, partitioned between ethyl acetate and 0.1 M H3P04, and the ethyl acetate layer was washed with brine, dried over Na2SO4, filtered, and concentrated to give crude product which was purified by recrystallization.
  • a binding assay for FK-506 was performed employing an immobilized form o the FKBP-CKS immunosuppressant assay reagent as described in Example 1 and an ascomycin-alkaline phosphatase conjugate as described in Example 2d.
  • a solution of the FKBP-CKS immunosuppressant assay reagent as described in Example 1 was prepared a a concentration of 10-35 ⁇ g/ml in 20 mM sodium phosphate buffer, pH 7.4, and 100 ⁇ l was incubated in the wells of a Immuno Plate MaxiSorpTM plate (Nunc, Naperville, IL) at ambient temperature for 2 hours in order to adsorb the immunosuppressant assay reagent to the walls of the wells.
  • PBS phosphate buffered saline
  • BSA bovine serum albumin
  • the temporal change in 405 nm absorbance was related to the amount of conjugate bound to the immobilized immunosuppressant assay reagent in the wells wherein a yellow product, para-nitrophenol, was produced as a result of the interaction of the alkaline phosphatase and para-nitrophenyl phosphate.
  • the FK- 506 blocked the binding of conjugate to the FKBP-CKS immunosuppressant assay reagent to thereby reduce the amount of para-nitrophenol product.
  • Total binding of the conjugate was determined from the amount of signal produced when no FK-
  • Nonspecific binding of the conjugate was determined from the amount of signal produced when 1-10 ⁇ M of FK-506, rapamycin, or ascomycin are present in the sample.
  • Shown in Figure 2 is a comparison of the amount of para-nitrophenol product formed, change in 405 nm absorbance, when 3.3 ⁇ g of the FKBP/CKS immunoassay reagent or FKBP was used to coat the wells of the plate in this Example 9.
  • the Total represents the results when 5 ⁇ g/ml of ascomycin-alkaline phosphatase was incubated in the wells without an inhibitor present.
  • 10 ⁇ M ascomycin was added to the wells with the ascomycin-alkaline phosphatase conjugate.
  • the use of FKBP/CKS resulted in a higher signal-to-noise, greater difference between the Total and Nonspecific binding, as compared to when FKBP is used.
  • FK-506 and rapamycin reduced, in a concentration dependent manner, the amount of signal produced when added to the assay of Example 9 when the wells were coated with 3 ⁇ g of FKBP-CKS immunoassay reagent and 0.5 ⁇ g/ml of ascomycin-alkaline phosphatase conjugate was used.
  • FK-506 and rapamycin concentration as low as 0.2 nM can be detected in such assay. Accordingly, standard curves, relating the known concentration of a purified immunosuppressive agent to the amount of signal produced, can be created and used to estimate the amount of the immunosuppressive agent in a sample.
  • a binding assay for H]-dihydro-FK-506 was performed employing an immobilized form of the FKBP-CKS immunosuppressant assay reagent of the present invention.
  • a solution of the FKBP-CKS immunosuppressant assay reagent as described in Example 1 was prepared at a concentration of 10-35 ⁇ g/ml in 20 mM sodium phosphate buffer, pH 7.4, and incubated in the wells of a Immuno Plate MaxiSorpTM plate (Nunc, Naperville, IL) at ambient temperature for
  • Total binding of the [3H]-dihydro-FK-506 was determined from the amount of signal produced when no FK-506 was present in the test sample.
  • Nonspecific binding of the [ 3 H]-dihydro-FK-506 was determined from the amount of signal produced when 1-10 ⁇ M of FK-506, rapamycin, or ascomycin were present in the sample.
  • a 1.4 nM concentration of [3H]-dihydro-FK-506 was incubated in the wells in the absence (Total) and presence (Nonspecific) of 4 ⁇ M ascomycin.
  • the results of [*-**H]-dihydro-FK-506 binding to the immobilized FKBP-CKS immunosuppressant assay reagent are shown in Figure 4. Standard curves as described in Example 9, relating the known concentration of a purified competitor to the amount of radioactive signal produced, can be created and used to determine the amount of the competitor in the test sample.
  • An assay format employing a multicomponent binding reagent system comprising (i) ascomycin conjugated to multiple sites on a macromolecule, such as bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), thyroglobulin, and the like (ii) an antiserum containing a first antibody which binds the ascomycin-macromolecule conjugate, and (iii) a second antibody which can bind to the first antibody to produce a detectable signal, was performed employing the following reagents:.
  • BSA bovine serum albumin
  • KLH keyhole limpet hemocyanin
  • thyroglobulin thyroglobulin
  • the FKBP-CKS immunosuppressant assay reagent as described in Example 1 was dissolved at a concentration of 10-20 ⁇ g/ml in 20 mM sodium phosphate buffer, pH 7.4, and added to the wells of a polystyrene microtiter plate and incubated at ambient temperature for 2 hours in order to immobilize the the immunosuppressant assay reagent to the well walls.
  • a solution of phosphate buffered saline (PBS), pH 7.4, containing 2 % bovine serum albumin (BSA) and 0.2 % Tween 20 was added to the wells and incubated for 30 minutes at ambient temperature. The wells were emptied and rinsed with 0.2 % Tween 20 in PBS, and 50 ⁇ l of a solution containing FK-506, or other inhibitor, in the
  • PBS/BSA/Tween 20 buffer was then added to the wells.
  • the wells were emptied and rinsed with PBS Tween 20, and 100 ⁇ l of a solution containing the rabbit anti-ascomycin antiserum in PBS/BSA Tween 20 was then added and incubated for 90 minutes at 37°C.
  • the wells were emptied and rinsed with PBS Tween 20, and 100 ⁇ l a solution containing the goat anti-rabbit IgG antiserum conjugated to alkaline phosphatase (diluted as recommended by the manufacturer) was then added and incubated for 90 minutes at 37°C.
  • the wells were emptied and rinsed with PBS Tween 20, and a solution of para-nitrophenyl phosphate (1 mg per ml in 0.1 M aminomethyl propanol) was then added to the wells and the temporal change in 405 nm absorbance was recorded.
  • the immobilized FKBP-CKS immunosuppressant assay reagent binds the multicomponent ligand system ("total” in Figure 5) in a manner which was inhibited by the presence of a sufficient concentration (1 ⁇ M) of FK-506 ("nonspecific” in Figure 5).
  • Figure 6 illustrates the effect of adding increasing concentrations of FK-506, rapamycin, and ascomycin in an assay format as described in Example 6, wherein FK-506 and rapamycin reduced the amount of signal from the conjugate at concentrations greater than 0.1 nM and ascomycin reduced the signal at concentrations greater than 1 nM.
  • Example 12 Detection Of FK-506 In Whole Blood
  • the immunosuppressant assay reagent of the present invention When performing an assay for determining immunosuppressive agents from a whole blood test sample employing the immunosuppressant assay reagent of the present invention, it may be necessary to separate the immunosuppressive agent from other components in the whole blood sample which may cause an interference in the assay.
  • a whole blood sample from a mouse was treated with acetonitrile, an organic solvent, to separate ascomycin from substances which may interfere in an assay.
  • CD-I mice were dosed with 5 mg/kg ascomycin orally and by intravenous injection. At intervals after dosing, the mice were euthanized with carbon dioxide and exsanguinated by cardiac puncture. Plasma was separated from red cells by centrifugation. Ascomycin was recovered from blood and plasma samples by treatment with water and acetonitrile. Samples were mixed with an equal volume of water for 30 seconds and acetonitrile was added to achieve an acetonitrile:water:sample ratio of 80:10:10 (v/v). After 16 hours at -20°C, the samples were centrifuged at 1000 X g for 10 minutes and the supernatants removed. The supernatants were dried in vacuo at ambient temperature, and the dried samples were then dissolved in the
  • PBS/BSA/Tween 20 buffer and the amount of ascomycin was determined according to the assay method described in Example 11.
  • a standard curve was prepared with ascomycin concentrations in the range of 0.1 to 10 nM.
  • the ascomycin content in the blood and plasma samples was determined by comparing the amount of conjugate signal produced when the sample was included in the assay to the amount of conjugate signal produced when known amounts of ascomycin were included in the assay ( Figures 7A and 7B).
  • An binding assay was performed employing calcineurin and the FKBP-CKS immunosuppressant assay reagent as described in Example 1.
  • the FKBP-CKS immunosuppressant assay reagent was dissolved at a concentration of 10-35 ⁇ g/ml in 2 M sodium phosphate buffer, pH 7.4, 100 ⁇ l of the immunoassay reagent solution was added to the wells of a Immuno Plate MaxiSorpTM (Nunc, Naperville, IL), and incubate at ambient temperature for 2 hours in order to immobilize the immunosuppressant assay reagent to the walls of the wells.
  • PBS phosphate buffered saline
  • BSA bovine serum albumin
  • the wells were emptied and rinsed with 0.2 % Tween 20 in PBS, and 50 ⁇ l of a solution containing FK-506 in 50 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 6 mM MgCl2, 0.1 mM CaCl2, 5 mM dithiothreitol, 0.2 % Tween 20, and 0.1 mg BSA per ml (Binding Buffer), or Binding Buffer alone, was added to the wells.
  • the temporal change in 405 nm absorbance was related to the amount of calcineurin bound to the immobilized immunosuppressant assay reagent in the wells.
  • some macrolide immunosuppressants such as FK- 506 enhance the binding of calcineurin to the FKBP-CKS immunusuppressant assay reagent and; therefore, increase the amount of para-nitrophenol product produced therefrom.
  • other macrolide immunosuppressants like rapamycin, are unable to enhance calcineurin binding to the FKBP-CKS and can not be directly measured with this method.
  • Figure 9 demonstrates the ability of FK-506 and a structurally related analog, ascomycin, to increase in a concentration dependent manner the amount of signal produced when the macrolides are included in the assay of this Example 13.
  • FK-506 and ascomycin are detected when they are present in the assay at concentrations greater than 1 nM. Because the level of signal is related to the concentration of the macrolide compound, standard curves can be created to relate the known concentration of a purified FK-506 to the amount of signal produced and used to estimate the unknown amount of the FK-506 in a sample.
  • Example 14 Binding Assay For FKBP
  • the FKBP-CKS immunosuppressant assay reagent as described in Example 1 was immobilized to the well walls of a polyvinylchloride microtiter plate by incubating a 10 ug mL solution thereof, in 20 mM tris, 0.9% NaCl, pH7.2(TBS), in the wells for 30 minutes . The wells were then blocked with 1% BSA, 0.2% Tween 20 in BSA.
  • microtiter wells were blocked by incubation for 15 minutes with a solution containing 10 mM Tris, 0.9 % NaCl, 0.05 % NaN3, 1 % BSA, and 0.2 % Tween 20, pH 7.4 (TBS-BSA-T;150 ⁇ l per well).
  • the FKBP-CKS immunosuppressant assay reagent as described in Example 1 was added to the wells of the microtiter plates at a concentration of 50 ng/ml in TBS-BSA-T (100 ⁇ l/well) and incubated one hour at room temperature.
  • the wells were emptied and rinsed with plate washing buffer (0.9 % NaCl, 0.1 % Azide, and 0.1 % Tween 20).
  • the amount of enzyme activity of the conjugate bound to the immobilized FKBP-CKS immunosuppressant assay reagent was quantitated by calculating the difference in the 405 nm absorbance of the wells at 5 minutes and 60 minutes. As shown in Figure 11 (superimposition of the curves indicates the close control of bound activity achievable with anti-CKS antibody immobilization), immobilization of the FKBP-CKS immunosuppressant assay reagent through monoclonal and polyclonal antibodies demonstrated that specific binding of the conjugate was more than 90% inhibitable by free FK-506 at 10 ng/mL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procédé de dosage et réactif pour la détermination de la présence ou de la quantité de ligands d'immunophilines et d'immunophilines au moyen d'une protéine de fusion recombinée comprenant (i) une protéine de liaison d'immunosuppresseur et (ii) une protéine hétérologue. La protéine de fusion recombinée peut également être utilisée pour l'évaluation de l'activité immunosuppressive d'immunosuppresseurs, ladite évaluation servant à déterminer l'efficacité d'un immunosuppresseur pendant le traitement d'un patient à l'aide dudit immunosuppresseur. De préférence, la protéine de fusion recombinée comprend un immunosuppresseur macrolide et la CTP:CMP-3-désoxy-D-manno-octulosonate cytidylyle transférase. Lorsqu'elle est utilisée dans un dosage par liaison, la protéine de fusion recombinée présente une réactivité plus élevée avec le ligand d'immunophiline subissant le dosage que ne le fait la protéine de liaison d'immunosuppresseur native. En particulier, un réactif utilisé pour le dosage d'un immunosuppresseur, comprenant la protéine de liaison de FK-506 (FKBP) et CKS immobilisée sur un matériau de support solide, présente, lorsqu'il est utilisé dans un dosage hétérogène compétitif, un rapport signal/bruit plus élevé que celui présenté par une FKBP native immobilisée sur un matériau de support solide, utilisée dans un tel type de dosage.
PCT/US1993/005197 1992-06-05 1993-06-01 Procedes et reactifs pour le dosage d'immnosuppresseurs WO1993025533A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44005/93A AU4400593A (en) 1992-06-05 1993-06-01 Methods and reagents for the determination of immunosuppressive agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89385892A 1992-06-05 1992-06-05
US07/893,858 1992-06-05

Publications (1)

Publication Number Publication Date
WO1993025533A1 true WO1993025533A1 (fr) 1993-12-23

Family

ID=25402239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/005197 WO1993025533A1 (fr) 1992-06-05 1993-06-01 Procedes et reactifs pour le dosage d'immnosuppresseurs

Country Status (2)

Country Link
AU (1) AU4400593A (fr)
WO (1) WO1993025533A1 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025072A1 (fr) * 1993-04-23 1994-11-10 American Home Products Corporation Conjugues de rapamycine et anticorps contre la rapamycine
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
WO1996012018A3 (fr) * 1994-10-14 1996-06-20 Salk Inst For Biological Studi Nouvelles immunophillines et acides nucleiques correspondants
WO1996041184A1 (fr) * 1995-06-07 1996-12-19 Abbott Laboratories Etalons et solutions d'etalonnage stabilises
US5821107A (en) * 1993-10-29 1998-10-13 New England Biolabs, Inc. Method for identifying anti-nematode compounds
WO1998045333A1 (fr) * 1997-04-09 1998-10-15 Isotechnika, Inc. Procede permettant la production d'anticorps a des sites specifiques de la rapamycine
US6011018A (en) * 1993-02-12 2000-01-04 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US6054436A (en) * 1993-02-12 2000-04-25 Board Of Trustees Of Leland S. Stanford Jr. Univ. Regulated apoptosis
US6063625A (en) * 1993-02-12 2000-05-16 Board Of Trustees Of Leland S, Stanford, Jr. University Regulated transcription of targeted genes and other biological events
US6165787A (en) * 1993-02-12 2000-12-26 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6313264B1 (en) 1994-03-08 2001-11-06 American Home Products Corporation Effector proteins of Rapamycin
EP1181938A3 (fr) * 1993-04-23 2002-03-20 American Home Products Corporation Conjugués de Rapamycine et anticorps
WO2003008453A1 (fr) * 2001-07-16 2003-01-30 Valtion Teknillinen Tutkimuskeskus Procede d'immobilisation de polypeptides
US6709873B1 (en) 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
US6891021B2 (en) 1993-02-12 2005-05-10 Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
US6972193B1 (en) 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
WO2006116727A2 (fr) 2005-04-27 2006-11-02 Dade Rehring Inc. Compositions et procedes pour detecter du sirolimus
US7196192B2 (en) 1999-08-24 2007-03-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US7244819B2 (en) 2001-06-22 2007-07-17 Roche Diagnostics Operations, Inc. Fusion polypeptides, vaccines and compositions of FKBP chaperones and target polypeptides
US7279562B2 (en) 1993-04-23 2007-10-09 Wyeth Rapamycin conjugates
WO2007149809A2 (fr) 2006-06-20 2007-12-27 Siemens Healthcare Diagnostics Inc. Étalon de tacrolimus et ses procédés d'utilisation
US7332472B2 (en) 2001-10-19 2008-02-19 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US7358229B2 (en) 1997-10-08 2008-04-15 Isotechnika Inc. Deuterated cyclosporin analogs and their use as immunomodulating agents
EP2181704A2 (fr) 2002-12-30 2010-05-05 Angiotech International Ag Liberation de medicaments a partir d'une compostion polymere a gelification rapide
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
US7993851B2 (en) 2006-12-29 2011-08-09 Abbott Laboratories Lysis reagent for use with capture-in-solution immunoassay
US8129127B2 (en) 2006-12-29 2012-03-06 Abbott Laboratories Assay for immunosuppressant drugs
US8221986B2 (en) 2006-12-29 2012-07-17 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
US8921642B2 (en) 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP3663405A1 (fr) 2013-06-11 2020-06-10 Takara Bio USA, Inc. Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation
US11573223B2 (en) * 2015-03-30 2023-02-07 Shanghai Inzex Biotechnology Co., Ltd. Extraction reagent of immunosuppressant drug for immunoassays
EP4183773A1 (fr) 2010-05-21 2023-05-24 Siemens Healthcare Diagnostics Inc. Réactifs zwitterioniques

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318612D0 (en) * 1993-09-08 1993-10-27 Sandoz Ltd An assay

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184162A2 (fr) * 1984-12-03 1986-06-11 Fujisawa Pharmaceutical Co., Ltd. Composés tricycliques, procédé pour leur préparation et composition pharmaceutique les contenant
EP0293892A2 (fr) * 1987-06-05 1988-12-07 Fujisawa Pharmaceutical Co., Ltd. Anticorps anti-FR-900506, substance et procédé d'essai enzymatique immunologique de haute sensibilité
US5047512A (en) * 1985-05-03 1991-09-10 Handschumacher Robert E Immobilized cyclophilin and methods of using such
WO1991017439A1 (fr) * 1990-05-09 1991-11-14 Children's Research Institute Dosage faisant appel a un recepteur et visant a determiner la presence de fk-506
US5109112A (en) * 1989-01-19 1992-04-28 Merck & Co., Inc. FK-506 cytosolic binding protein
US5124255A (en) * 1988-03-11 1992-06-23 Abbott Laboratories CKS method of protein synthesis
US5196352A (en) * 1989-01-19 1993-03-23 Merck & Co., Inc. New FK-506 cytosolic binding protein

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184162A2 (fr) * 1984-12-03 1986-06-11 Fujisawa Pharmaceutical Co., Ltd. Composés tricycliques, procédé pour leur préparation et composition pharmaceutique les contenant
US5047512A (en) * 1985-05-03 1991-09-10 Handschumacher Robert E Immobilized cyclophilin and methods of using such
EP0293892A2 (fr) * 1987-06-05 1988-12-07 Fujisawa Pharmaceutical Co., Ltd. Anticorps anti-FR-900506, substance et procédé d'essai enzymatique immunologique de haute sensibilité
US5124255A (en) * 1988-03-11 1992-06-23 Abbott Laboratories CKS method of protein synthesis
US5109112A (en) * 1989-01-19 1992-04-28 Merck & Co., Inc. FK-506 cytosolic binding protein
US5196352A (en) * 1989-01-19 1993-03-23 Merck & Co., Inc. New FK-506 cytosolic binding protein
WO1991017439A1 (fr) * 1990-05-09 1991-11-14 Children's Research Institute Dosage faisant appel a un recepteur et visant a determiner la presence de fk-506

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOTECHNIQUES, Volume 8, Number 5, issued 1990, T.J. BOLLING et al., "An Escherichia Coli Expression Vector for High-Level Production of Heterologous Proteins in Fusion with CMP-KDO Synthetase", pages 488-492. *
CELL, Volume 66, issued 23 August 1991, J. LIU et al., "Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes", pages 807-815. *
N.R. ROSE et al., "Manual of Clinical Immunology", published 1976, by AMERICAN SOCIETY FOR MICROBIOLOGY (WASHINGTON, D.C.), see pages 506-512. *
SCIENCE, Volume 226, issued 02 November 1984, R.E. HANDSCHUMACHER et al., "Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin A", pages 544-547. *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 261, Number 34, issued 05 December 1986, R.C. GOLDMAN et al., "Primary Structure of CTP:CMP-3-Deoxy-D-Manno-Octulosonate Cytidylyltransferase (CMP-KDO Synthetase) from Escherichia Coli", pages 15831-15835. *
TRANSPLANTATION PROCEEDINGS, Volume 22, Number 3, issued June 1990, M.I. LORBER et al., "Cyclophilin Binding: A Receptor-Mediated Approach to Monitoring Cyclosporine Immunosuppressive Activity Following Organ Transplantation", pages 1240-1244. *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316418B1 (en) 1993-02-12 2001-11-13 Board Of Trustees Of Leland Stanford Junior University Regulated apoptosis
US8084596B2 (en) 1993-02-12 2011-12-27 The Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
US6972193B1 (en) 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US6891021B2 (en) 1993-02-12 2005-05-10 Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
US6165787A (en) * 1993-02-12 2000-12-26 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US6140120A (en) * 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US6011018A (en) * 1993-02-12 2000-01-04 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US6043082A (en) * 1993-02-12 2000-03-28 Board Of Trustees Of Leland Stanford Jr. Univ. Regulated transcription of targeted genes and other biological events
US6054436A (en) * 1993-02-12 2000-04-25 Board Of Trustees Of Leland S. Stanford Jr. Univ. Regulated apoptosis
US6063625A (en) * 1993-02-12 2000-05-16 Board Of Trustees Of Leland S, Stanford, Jr. University Regulated transcription of targeted genes and other biological events
EP1181938A3 (fr) * 1993-04-23 2002-03-20 American Home Products Corporation Conjugués de Rapamycine et anticorps
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
WO1994025072A1 (fr) * 1993-04-23 1994-11-10 American Home Products Corporation Conjugues de rapamycine et anticorps contre la rapamycine
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US7279562B2 (en) 1993-04-23 2007-10-09 Wyeth Rapamycin conjugates
US7897733B2 (en) 1993-04-23 2011-03-01 Pfizer, Inc. Rapamycin conjugates and antibodies
US6541612B2 (en) 1993-04-23 2003-04-01 Wyeth Monoclonal antibodies obtained using rapamycin position 27 conjugates as an immunogen
US5821107A (en) * 1993-10-29 1998-10-13 New England Biolabs, Inc. Method for identifying anti-nematode compounds
US6713607B2 (en) 1994-03-08 2004-03-30 Wyeth Effector proteins of Rapamycin
US6313264B1 (en) 1994-03-08 2001-11-06 American Home Products Corporation Effector proteins of Rapamycin
WO1996012018A3 (fr) * 1994-10-14 1996-06-20 Salk Inst For Biological Studi Nouvelles immunophillines et acides nucleiques correspondants
WO1996041184A1 (fr) * 1995-06-07 1996-12-19 Abbott Laboratories Etalons et solutions d'etalonnage stabilises
US6649595B2 (en) 1995-06-07 2003-11-18 Ariad Gene Therapeutics, Inc. Regulation of biological events using novel compounds
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
WO1998045333A1 (fr) * 1997-04-09 1998-10-15 Isotechnika, Inc. Procede permettant la production d'anticorps a des sites specifiques de la rapamycine
US6709873B1 (en) 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
US7538189B2 (en) 1997-10-08 2009-05-26 Isotechnika Inc. Methods of making deuterated cyclosporin analogs
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US7358229B2 (en) 1997-10-08 2008-04-15 Isotechnika Inc. Deuterated cyclosporin analogs and their use as immunomodulating agents
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US7196192B2 (en) 1999-08-24 2007-03-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US7244575B2 (en) 2001-06-22 2007-07-17 Roche Diagnostics Corporation Soluble complex comprising a retroviral surface glycoprotein
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
US7244819B2 (en) 2001-06-22 2007-07-17 Roche Diagnostics Operations, Inc. Fusion polypeptides, vaccines and compositions of FKBP chaperones and target polypeptides
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
WO2003008453A1 (fr) * 2001-07-16 2003-01-30 Valtion Teknillinen Tutkimuskeskus Procede d'immobilisation de polypeptides
US7078192B2 (en) 2001-07-16 2006-07-18 Valtion Teknillinen Tutkimuskeskus Method for immobilization of polypeptides
US9765119B2 (en) 2001-10-19 2017-09-19 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US7332472B2 (en) 2001-10-19 2008-02-19 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US10472394B2 (en) 2001-10-19 2019-11-12 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
USRE48226E1 (en) 2001-10-19 2020-09-29 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
EP2181704A2 (fr) 2002-12-30 2010-05-05 Angiotech International Ag Liberation de medicaments a partir d'une compostion polymere a gelification rapide
EP1880215A4 (fr) * 2005-04-27 2008-05-14 Dade Behring Inc Compositions et procédés pour détecter du sirolimus
WO2006116727A2 (fr) 2005-04-27 2006-11-02 Dade Rehring Inc. Compositions et procedes pour detecter du sirolimus
EP2037944A4 (fr) * 2006-06-20 2010-10-13 Siemens Healthcare Diagnostics Étalon de tacrolimus et ses procédés d'utilisation
US8153594B2 (en) 2006-06-20 2012-04-10 Siemens Healthcare Diagnostics Inc. Tacrolimus standard and methods of using same
WO2007149809A2 (fr) 2006-06-20 2007-12-27 Siemens Healthcare Diagnostics Inc. Étalon de tacrolimus et ses procédés d'utilisation
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US8541554B2 (en) 2006-07-21 2013-09-24 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US8129127B2 (en) 2006-12-29 2012-03-06 Abbott Laboratories Assay for immunosuppressant drugs
US8404452B2 (en) 2006-12-29 2013-03-26 Abbott Laboratories Assay for immunosuppressant drugs
US8440416B2 (en) 2006-12-29 2013-05-14 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
US8329415B2 (en) 2006-12-29 2012-12-11 Abbott Laboratories Lysis reagent for use with capture-in-solution immunoassay
US8697365B2 (en) 2006-12-29 2014-04-15 Abbott Laboratories Non-denaturing lysis reagent
US8221986B2 (en) 2006-12-29 2012-07-17 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
US7993851B2 (en) 2006-12-29 2011-08-09 Abbott Laboratories Lysis reagent for use with capture-in-solution immunoassay
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
US8921642B2 (en) 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP4183773A1 (fr) 2010-05-21 2023-05-24 Siemens Healthcare Diagnostics Inc. Réactifs zwitterioniques
EP3663405A1 (fr) 2013-06-11 2020-06-10 Takara Bio USA, Inc. Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation
EP4491726A2 (fr) 2013-06-11 2025-01-15 Takara Bio USA, Inc. Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation
US11573223B2 (en) * 2015-03-30 2023-02-07 Shanghai Inzex Biotechnology Co., Ltd. Extraction reagent of immunosuppressant drug for immunoassays

Also Published As

Publication number Publication date
AU4400593A (en) 1994-01-04

Similar Documents

Publication Publication Date Title
WO1993025533A1 (fr) Procedes et reactifs pour le dosage d'immnosuppresseurs
EP0710110B1 (fr) Anticorps de rapamycines a cycle ouvert
EP0674178B1 (fr) Essai immunologique de cyclosporine
US7625726B2 (en) Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
RU2175672C2 (ru) Моноклональное антитело, способное специфически распознавать рапамицин (варианты), набор для иммунотестирования
JP4753514B2 (ja) タクロリムスに対するモノクローナル抗体およびタクロリムスのためのイムノアッセイ
US5164495A (en) Method for preparing a dicarboxylic acid half-acid ester of FK506
JP3750020B2 (ja) Ｃ末端修飾タンパク質およびその製造方法、ならびに、ｃ末端修飾タンパク質の製造に用いる修飾剤および翻訳テンプレート、ならびに、ｃ末端修飾タンパク質を用いたタンパク質相互作用の検出方法
KR100252688B1 (ko) 면역검정법에사용하기위한간섭억제제
US6632615B2 (en) Method for isolating a target biological material, capture phase, detecting phase and reagent containing them
JP2006517657A (ja) サキシトキシン−ビオチンコンジュゲートを用いたサキシフィリンの検出および同定
WO1999021580A1 (fr) Reactifs et dosage immunologique de detection et de determination quantitative de mycothiol et de ses precurseurs
Yao et al. Enzyme immunoassay for macrolide antibiotics: characterization of an antibody to 23-amino-O-mycaminosyltylonolide
US6780418B1 (en) Reagents and immunoassay for the detection and quantitative determination of mycothiol and precursors thereof
US4772697A (en) Tricylic antidepressant conjugates to antigens and enzymes
USRE40596E1 (en) Rapamycin assay

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase